Literature DB >> 19013346

Epidemiology of candidemia in intensive care units.

Emilio Bouza1, Patricia Muñoz.   

Abstract

The incidence of candidemia in the overall population ranges from 1.7 to 10 episodes per 100,000 inhabitants and Candida is one of the ten leading causes of bloodstream infections in developed countries. An estimated 33-55% of all episodes of candidemia occur in intensive care units (ICU) and are associated with mortality rates ranging from 5% to 71%. Candida fungemia may have an endogenous or an exogenous origin, and in recent years a growing proportion of episodes of candidemia have been caused by Candida species other than albicans. The most important independent conditions predisposing to candidemia in ICU patients include prior abdominal surgery, intravascular catheters, acute renal failure, parenteral nutrition, broad-spectrum antibiotics, a prolonged ICU stay, the use of corticosteroids and mucosal colonization with Candida. In recent years, several studies have shown that ICU patients with mucosal Candida colonization, particularly if multifocal, are at a higher risk for invasive candidiasis, and that colonization selects a population amenable to antifungal prophylaxis or empirical therapy. Candidemia in ICUs is associated with a considerable increase in hospital costs and length of hospital stay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013346     DOI: 10.1016/S0924-8579(08)70006-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  55 in total

1.  Identification of Azole Resistance Markers in Clinical Isolates of Candida tropicalis Using cDNA-AFLP Method.

Authors:  Ali Kanani; Farideh Zaini; Parivash Kordbacheh; Mehraban Falahati; Sassan Rezaie; Roshanak Daie; Shirin Farahyar; Mahin Safara; Roohollah Fateh; Ebrahim Faghihloo; Azam Fattahi; Mansour Heidari
Journal:  J Clin Lab Anal       Date:  2015-04-14       Impact factor: 2.352

2.  Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period.

Authors:  Jessica Mencarini; Elisabetta Mantengoli; Lorenzo Tofani; Eleonora Riccobono; Rossella Fornaini; Filippo Bartalesi; Giampaolo Corti; Alberto Farese; Patrizia Pecile; Luca Boni; Gian Maria Rossolini; Alessandro Bartoloni
Journal:  Infection       Date:  2018-04-13       Impact factor: 3.553

3.  Accurate and rapid identification of Candida spp. frequently associated with fungemia by using PCR and the microarray-based Prove-it Sepsis assay.

Authors:  Anne Aittakorpi; Pentti Kuusela; Pirkko Koukila-Kähkölä; Martti Vaara; Michael Petrou; Vanya Gant; Minna Mäki
Journal:  J Clin Microbiol       Date:  2012-09-05       Impact factor: 5.948

4.  Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies.

Authors:  Narcisa Marangoci; Mihai Mares; Mihaela Silion; Adrian Fifere; Cristian Varganici; Alina Nicolescu; Calin Deleanu; Adina Coroaba; Mariana Pinteala; Bogdan C Simionescu
Journal:  Results Pharma Sci       Date:  2011-08-01

5.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Authors:  Cristina Rueda; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

7.  In-vitro Inhibition of Biofilm Formation in Candida albicans and Candida tropicalis by Heat Stable Compounds in Culture Filtrate of Aspergillus flavus.

Authors:  Sayan Bhattacharyya; Prashant Gupta; Gopa Banerjee; Amita Jain; Mastan Singh
Journal:  J Clin Diagn Res       Date:  2013-10-05

Review 8.  Invasive fungal infections: the challenge continues.

Authors:  Antonino Gullo
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.

Authors:  S M Heimann; O A Cornely; H Wisplinghoff; M Kochanek; D Stippel; S A Padosch; G Langebartels; H Reuter; M Reiner; A Vierzig; H Seifert; M J G T Vehreschild; J Glossmann; B Franke; J J Vehreschild
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

10.  Normal adaptation of Candida albicans to the murine gastrointestinal tract requires Efg1p-dependent regulation of metabolic and host defense genes.

Authors:  Jessica V Pierce; Daniel Dignard; Malcolm Whiteway; Carol A Kumamoto
Journal:  Eukaryot Cell       Date:  2012-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.